Newsletter SignupSearch

Cohen Veterans Bioscience is doing things differently. Our approach is to build enabling platforms with strategic partners and to adopt a team science approach to fast-track solutions in years, not decades.

We bring together the brightest minds and deploy the most innovative scientific tools with an emphasis on scale, risk-minimization, efficiency and speed to advance our understanding of PTSD and TBI. Through rigorous research and breaking down traditional silos, we’re working to bring more accurate diagnostic tests for PTSD and TBI to patients using big data, digital health and innovative technology to match patients to the right treatment.

A pathway to progress in years, not decades

The Status Quo

  • Animal models that fail to translate to human studies
  • Checklist-based self-report symptom assessments
  • Data collection methods that limit big data applications and collaborative science
  • Limited outcome measurement tools that fail to capture the full breadth of symptoms
  • Small, uncoordinated studies that limit biomarker discovery
  • A siloed approach to science that stalls progress

CVB’s Evidence-Driven Approach to Advancing Precision Medicine for Brain Trauma

  • Reproducible animal models that accurately predict treatment response in humans
  • New technologies and tools to drive diagnostic and treatment biomarker discovery tailored to each patient’s unique biology
  • Advanced data analytics that leverage in house expertise and a cloud-based platform to facilitate analysis and sharing across datasets
  • More objective outcome measurement tools that capture the symptoms that matter most to the patient
  • Large, deeply phenotyped cohort studies for biomarker discovery and validation at scale
  • Embracing team science to foster innovation and speed solutions across diseases

Moving away from the one patient, one treatment approach.

Advancing the scientific understanding of PTSD and TBI

Our research and advocacy aim to improve the lives of all people who experience the effects of trauma by:

  • Advancing our understanding of TBI and PTSD through rigorous research, including discovering genetic factors and building predictive data models.
  • Fast-tracking the development of easy-to-use diagnostic tests and guidelines to diagnose TBI and PTSD quickly and accurately.
  • Advancing research that can help match patients to the most effective treatments, including wellness, digital health, drug and device approaches.
  • Advocating for policies that prioritize new solutions for all those affected by brain trauma at the federal, state, and local levels. Learn more about our advocacy efforts.
Learn More About our Research and Advocacy Efforts

From Brain Trauma to Brain Health

Our research to fast-track diagnostics and treatments for PTSD and TBI can be applied to advance solutions for other brain disorders.

Support our efforts

Magali Haas, MD, PhD
CEO & President

View Bio

Magali Haas, MD, PhD

CEO & President

Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early and late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.

Nicole Harmon, PhD
Chief Operating Officer

View Bio

Nicole Harmon, PhD

Chief Operating Officer

Nicole Harmon brings more than 18 years of experience in psychology, philanthropy, patient advocacy, public health, and clinical research, most recently as the Chief Operating Officer and Chief of Staff for Clinical Data Interchange Standards Consortium (CDISC), FDA’s partner for data standards. During her tenure there she transformed CDISC’s financial roadmaps, program management and global brand. Additionally, she developed and managed complex partnerships with leading U.S and International funding partners, U.S. FDA, Japan PMDA, European Medicines Agency, NIH, WHO, EU’s Innovative Medicines Initiatives, Global Patient Foundations and others to drive data standards and sharing initiatives and oversaw grants cultivation and management successfully achieving funding for and administering multiple large-scale projects.  Prior to her time with CDISC, Dr. Harmon evaluated patients with Traumatic Brain Injury and Psychiatric conditions in a post-acute rehabilitation hospital. Nicole earned her doctorate in Counselor Education and Supervision at Texas Tech University with dissertation focus on understanding the caregivers experience associated with acquired brain injury following discharge from rehabilitation.

Allyson Gage, PhD
Chief Medical Officer

View Bio

Allyson Gage, PhD

Chief Medical Officer

Dr. Allyson T. Gage is a neuroscientist and drug development executive, who has over 18 years of experience leading teams in all phases of clinical development. She has been responsible for the overall strategic and clinical development of small molecules, biologics, and cellular therapies for the treatment of central nervous system disorders, including depression, alcohol dependence, Alzheimer’s dementia, neuropathic pain, traumatic brain injury, and spinal cord injury. Allyson has a proven track record in partnering with therapeutic area clinicians, US and International regulators, patient groups, and data scientists to translate pre-clinical information into human evaluation, to design informative clinical trial protocols, and ensure a regulatory path with approvable and clinically meaningful outcome measures. Prior to joining Cohen Veterans Bioscience, Allyson’s most recent experience was focused in the field of regenerative medicine, working toward the development of a therapeutic for spinal cord injury. Allyson earned her BA from Rutgers College in New Brunswick, NJ and her MS and PhD in neuroscience from Albert Einstein College of Medicine, New York.

Lee Lancashire, PhD
Chief Information Officer

View Bio

Lee Lancashire, PhD

Chief Information Officer

Lee Lancashire, PhD has over 15 years of experience in machine learning and statistics. His PhD was focused on the development of artificial neural network based methodologies where he was involved in many of the first applications of neural nets to high dimensional datasets in bioinformatics. Prior to joining Cohen Veterans Bioscience, Lee spent over five years within the IP&Science business of Thomson Reuters where he established and led the machine learning and statistical data analysis team. Here he held global responsibility for managing and delivering analytical projects, serving the majority of the top 10 pharmaceutical companies, as well as government, academic and non-profit organizations. These projects focused on utilizing advanced machine learning approaches in the molecular profiling of disease for biomarker discovery, patient stratification and drug target identification. Lee completed his post-doctoral research in Biostatistics and Bioinformatics at the Paterson Institute for Cancer Research, a Cancer Research UK core facility. He has also worked as a bioinformatics project lead in personalized medicine and diagnostics companies CompanDX and Almac Diagnostics. He has published in over 30 key industry journals and holds several patents around the use of neural networks in the biomedical domain. In his free time Lee devotes time volunteering as a trustee for the Ichthyosis Support Group, a charity that supports individuals and families affected by a group of rare skin disorders.

Eugene Rakhmatulin
Chief Technology Officer

View Bio

Eugene Rakhmatulin

Chief Technology Officer

Eugene Rakhmatulin is launching a new department at Cohen Veterans Bioscience dedicated to highly sophisticated technology development. He has more than two decades of experience in Information Technologies (IT), including 15+ years in Life Sciences field. Eugene’s work has been largely focused on software development, systems architecture and management. Previously, Eugene was the Senior Director of Enabling Technologies and Informatics Delivery at Clarivate Analytics, formerly Thomson Reuters Intellectual Property & Science business. In this role, he led a global Professional Services Technology organization that was dedicated to designing and implementing data integration solutions, analytics tools and content services for major pharmaceutical companies, government, academia and non-profit organizations. Eugene joined Thomson Reuters in 2010 through an acquisition of GeneGo, the leading provider of software and content for Systems Biology. There, he served as the Head of IT and software Development. Eugene earned his MS in Computer Science and Engineering from the Moscow Aviation Institute (State Technical University) in Moscow, Russia.

Peter Hoehn
Executive Vice President, Marketing Strategy, Development and Impact

View Bio

Peter Hoehn

Executive Vice President, Marketing Strategy, Development and Impact

Peter Hoehn is a proven healthcare business leader with 25+ years’ experience in a variety of commercial and strategy roles, predominantly at Johnson & Johnson.  Throughout his career Peter has demonstrated the ability to develop insight driven strategies in complex markets and mobilize internal and external partners to achieve results.  He brings broad-based commercial, strategy and leadership experiences across Pharmaceuticals, Diagnostics, Digital Health and Precision Medicine, including brand positioning and messaging, reimbursement and market access, global launches, organizational capability building, business model innovation, new opportunity evaluation, business development, and policy.

Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer Peter moved into various strategy, marketing and sales management roles at BMS before joining Johnson & Johnson in 2003.  He started at J&J as Global Commercial Leader for Reminyl, an Alzheimer’s drug, and was then promoted to Global Marketing Leader, Neurology, where he had global commercial responsibility for in-line neurology products as well as products in late stage of development.

In 2008 Peter joined J&J’s Ortho Clinical Diagnostics organization as Vice President for WW Marketing and Strategic Marketing, responsible for long-term organizational strategy and a large global diagnostics business.  In 2012 Peter moved back to J&J’s pharmaceuticals business as Precision Medicine Commercial Strategy Leader. In this role, Peter helped develop J&J’s Precision Medicine strategy, and built and led the Precision Medicine Commercial Team which was responsible for leading strategic marketing and market access for companion and complementary diagnostics across all Therapeutic Areas.

In his most previous role before joining CVB, Peter was Head, Commercial Strategy for J&J Science for Minds, a new organization focused on innovative development models and digital solutions to address Serious Mental Illness and dementia.  In this position he developed the strategy, portfolio recommendations, investment approach, external collaborations, and business models for new mental health and brain health digital business ventures.

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.

Mark Zervas, PhD
Deputy Director, Translational Research & Development

View Bio

Mark Zervas, PhD

Deputy Director, Translational Research & Development

Mark Zervas earned his Ph.D in Neuroscience at the Albert Einstein College of Medicine, was a postdoctoral fellow at the NYU School of Medicine, and was the Manning Assistant Professor of Biology in the MCB department at Brown University. Mark served as Senior Scientist at Amgen, where he led a research team that used human genetics to discover novel therapeutic targets and hIPSC-derived dopamine neurons for understanding target biology and mechanisms underlying Parkinson’s Disease, including mitochondrial dysfunction. Most recently, Mark led a team at Alnylam Pharmaceuticals using RNAi to treat ocular diseases.

Nicole Bjorklund, PhD
Director, Translational Research & Development

View Bio

Nicole Bjorklund, PhD

Director, Translational Research & Development

Nicole Bjorklund, PhD, brings her expertise in biochemistry, translational neuroscience and biomarker development to the RAPID-Dx program, focused on advancing biomarker discovery and validation in post-traumatic stress disorder and traumatic brain injury. Prior to joining CVB, Nicole led the development and management of the Diagnostics Accelerator initiative at the Alzheimer’s Drug Discovery Foundation, which supports the advancement of biomarkers for use in drug development for Alzheimer’s disease and related dementias. Nicole started her career as an Assistant Research Professor and Operations Director of the Biomarker and Biorepository core facilities at Albert Einstein College of Medicine. Her laboratories, as part of the CTSA-supported Institute of Clinical and Translational Research, supported the large number of clinical research studies at Einstein and Montefiore Medical Center in the Bronx, NY. Nicole completed postdoctoral training at the University of Texas Medical Branch, where she investigated molecular resistance mechanisms to Alzheimer’s disease. She earned a bachelor’s degree in chemistry from Boise State University and a doctorate in biochemistry at Washington State University.

Eric Prager, PhD
Associate Director, Translational Research & Development

View Bio

Eric Prager, PhD

Associate Director, Translational Research & Development

Eric Prager is currently working on key initiatives including the Brain Trauma Blueprint, State of the Science Summits and grants management. Previously, Eric held a postdoctoral position at the Albert Einstein College of Medicine. Following this, Eric joined Wiley where he was named Editor-in-Chief of the Journal of Neuroscience Research (JNR) and also worked to improve scientific rigor by developing specific standards for more transparency including how data was reported and described. JNR continues to use these standard today. Earlier in his career, Eric was a postdoctoral fellow at Stony Brook University investigating how dopamine oppositely modulates synaptic integration in striosome and matrix compartments of the striatum. His work has led him to a leadership position on the European College of Neuropsychopharmacology’s Preclinical Data Forum Network. Eric is a member of the Advisory Committee to the NIH Director Working Group on Enhancing Reproducibility and Rigor in Animal Research. Eric received his master’s degree in counseling psychology from the University of Denver and his PhD in Neuroscience from the Uniformed Services University.

Sanjiv Bhave, PhD
Senior Program Manager, Translational Research & Development

View Bio

Sanjiv Bhave, PhD

Senior Program Manager, Translational Research & Development

Sanjiv Bhave, Ph.D. is an experienced neuroscientist and all throughout his professional journey, across different continents, he has worked, in academia and industry, in a wide range of fields in neuroscience, molecular biology, biochemistry, genomics and proteomics. His background, a unique blend of disciplines such as neurosciences, genetical genomics, transcriptomics/proteomics and bioinformatics, enables him to quickly take the lead on any type of project  – “traditional” hypothesis driven projects or “global” hypothesis driven projects such as those designed to assess “candidate genes or biomarkers”. He has worked at the University of Colorado School of Medicine for twenty plus years on a number of different aspects of neuroscience including developing a database, and associated data analyses tools, for the whole transcriptome in the whole brain of close to hundred different strains of mice and rats. He earned his Ph.D. in Biochemistry from the MS University of Baroda, India and did postdoctoral studies at the Downstate Medical Center, SUNY, Brooklyn and Wayne State School of Medicine Detroit.

Elena Rotondo, PhD
Program Manager, Translational Research & Development

View Bio

Elena Rotondo, PhD

Program Manager, Translational Research & Development

Elena Rotondo is an experienced neuroscientist with expertise in the neurobiology of experience-dependent changes in the brain. Elena earned an MS in neuroscience from the University of Wisconsin, where she researched the molecular mechanisms of fear learning. She also earned a PhD in neuroscience from Rutgers University, where she used epigenetic interventions to facilitate learning.

Saheed Adeyeri, CCRP
Clinical Trial Manager, Clinical Programs

View Bio

Saheed Adeyeri, CCRP

Clinical Trial Manager, Clinical Programs

Saheed Adeyeri is a certified clinical research scientist and well-respected thought leader in the field, is managing clinical trial programs. Saheed has extensive industry experience having worked in clinical research management and programming at Ortho Clinical Diagnostics, Becton Dickinson and InVentiv Health Clinical as well as Sanofi Pharmaceuticals. Saheed’s core competencies are end-to-end execution and management of clinical trials everything from study site start-up and monitoring to milestone tracking. He has studied and trained extensively completing Harvard University Fundamentals of Clinical Trials, the FDA Bioresearch Monitoring Program and an accreditation program in London. Saheed holds a BS with distinction in microbiology from the University of Ilorin, Nigeria.

Andrew Thompson, PhD
Associate Director, Data Science

View Bio

Andrew Thompson, PhD

Associate Director, Data Science

Andrew is a data scientist leading the RAPID-Dx program advance biomarker discovery and validation in post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Previously, he worked at PatientsLikeMe where he led analyses of patient-reported health data and multi-omic biological data to define predictive biomarkers and characterize disease sub-types. During his graduate degree training in neurobiology, Andrew focused on plasticity in the developing visual system, investigating a role for feedback projections in the fine-tuning of circuits during development. Prior to his PhD, Andrew worked with the discovery group at Vanda Pharmaceuticals, where he performed pharmacogenomics research in support of a phase 3 clinical trial and expression profiling studies – all in an effort to elucidate common gene signatures and repurpose existing drugs for new indications. Andrew earned his BS in biology from the University of Maryland and his PhD in biological and biomedical sciences from Harvard University.

Emanuele Libertini, PhD
Associate Director, Data Science

View Bio

Emanuele Libertini, PhD

Associate Director, Data Science

Emanuele has a background in bioinformatics, network biology, genomics, metagenomics and epigenomics. He has worked in the academic field at University College London and Institut Pasteur Paris before moving to the private sector with Thomson Reuters and Clarivate. His interests lie in integrating and interpreting biological datasets representing multiple levels of regulation of molecular mechanisms with quantitative methods suited to capture resolution-dependent signals. His experience includes exposure to modelling plant signalling networks, host-pathogen relationships in the infection of human cells, and epigenomic regulation in humans. In the last five years he has focused on modelling molecular mechanisms of disease in a broad range of pharma projects, including pathologies of the brain and the nervous system.

Raphael Gerraty, PhD
Associate Director, Data Science

View Bio

Raphael Gerraty, PhD

Associate Director, Data Science

Raphael has years of experience working with human neuroimaging data, computational cognitive models, and Bayesian statistics. Prior to graduate school, he worked as an imaging data analyst in Neuropsychiatry at the Hospital of the University of Pennsylvania. He received his PhD in Psychology from Columbia University in 2018, where his research focused on the dynamics of large-scale cortical networks during reinforcement learning. In his postdoctoral research, he studied neural representations of uncertainty and used deep neural networks to model the human visual system.

Rebecca Reh, PhD
Senior Manager, Data Science

View Bio

Rebecca Reh, PhD

Senior Manager, Data Science

Rebecca is a data scientist with over 6 years of experience in the analysis of neuroimaging data. Before joining Cohen Veterans Bioscience, Rebecca worked as a Research Associate at the University of British Columbia, where her work focused on elucidating EEG biomarkers of developmental plasticity in human language acquisition, including developing classification models of infant speech sound perception. She has experience with longitudinal data analysis and modeling, leading a large longitudinal study examining the impact of in utero Serotonin Reuptake Inhibitor (SRI) exposure on children’s language development. Rebecca received her Ph.D. in Neuroscience from Harvard University, where her research explored neurobiological mechanisms underlying experience driven plasticity in the developing visual system. She has received multiple prestigious fellowships for her work, including from the Canadian Institute for Advanced Research and the National Science Foundation.

Nikolai Shokhirev, PhD
Senior Data Scientist

View Bio

Nikolai Shokhirev, PhD

Senior Data Scientist

Dr. Shokhirev received a Master of Science Degree in theoretical physics from Novosibirsk State University, Russia, and his Doctor of Philosophy degree in Physics and Mathematics from the Russian Academy of Sciences, Novosibirsk. Dr. Shokhirev has conducted research in quantum mechanics, magnetic spectroscopy, econophysics, stochastic processes and kinetics. He has also been involved in data analysis and processing in pulse spectroscopy, indirect measurements and remote sensing, scientific, engineering and financial data. He has published over 70 papers in those fields. Dr. Shokhirev joined the Digital Health team to apply his data science skills to the emerging area of remote health monitoring and healthcare.

Kimon Kotronis, MD, MSc, MBA
Director, Solutions Architecture, Technology Development

View Bio

Kimon Kotronis, MD, MSc, MBA

Director, Solutions Architecture, Technology Development

Kimon Kotronis is the Director of Solutions Architecture, responsible for defining and designing functionality and helping to drive development of all CVB software solutions, including BRAIN Commons, Cohen Veterans Bioscience’s cloud-based research and discovery platform for the brain health community. Kimon has more than 15 years of experience in Health Informatics and Life Sciences Technology projects, across a wide spectrum of public and private sector organizations internationally. Prior to joining Cohen Veterans Bioscience, Kimon led the Life Sciences Enabling Technologies engagement team, driving digital transformation solutions at all stages of the Drug Development process for many of the top 20 global pharmaceuticals and many academic and government research organizations. Kimon earned his MD from the Aristotle University of Thessaloniki, Greece, his MSc in Medical Informatics from City University, London and his MBA from Cass Business School, London.

Zhanna Rozenberg
Director, Technology Development

View Bio

Zhanna Rozenberg

Director, Technology Development

Zhanna received her BA at Cornell University where she triple majored in Economics, Comparative Literature, and an College Scholars major that tread on philosophy, critical theory, and sociology. She completed a minor in East Asian Studies. She later went to study statistics, econometrics, and machine learning at the Ruprecht-Karls-Universität Heidelberg, Universität Mannheim, and the Metis’s data science bootcamp. Zhanna is interested in making technology that helps people live more meaningful lives, using data to improve human performance. Zhanna is active in NY’s meetup culture focusing on data science, neuroscience, wearables, IoT, and habit design. Zhanna’s major individual project, “Hindsight”, explored the interaction between subjective and objective measures of human performance.

Matthew Springer
Senior Cloud Engineer, Technology Development

View Bio

Matthew Springer

Senior Cloud Engineer, Technology Development

Matthew Springer has over 25 years of experience in the IT industry. He has extensive experience in computer manufacture, IT infrastructure management, database administration and cloud engineering. Prior to joining Cohen Veterans Bioscience, he was a Senior Development Operations Engineer in the Life Sciences division of Clarivate Analytics, formerly the Thomson Reuters Intellectual Property & Science business. He was responsible for the design and implementation of the cloud infrastructure within the Professional Services organization. He was also responsible for the management of their database infrastructure and the automation of their software deployments. Matthew joined Thomson Reuters in 2011 as a Senior Database Engineer. Matthew is involved in various California-based initiatives to feed and support the homeless community. He also has a keen interest in Cinematography, Videography and Photography.

Isabel Curro
Senior Manager, Technology Development

View Bio

Isabel Curro

Senior Manager, Technology Development

Isabel is working with the Digital Health team on device validation, data analysis and protocol development for internal testing and Sleepwell projects. Previously, she completed an engineering internship with VERO Biotech, a medical device start-up based in Atlanta. Isabel also conducted research on how to combat antibiotic- resistant bacteria and how to develop nanoparticles for targeted drug delivery at the Lab for Synthetic Immunity at Georgia Tech. She also interned with Siemens in Erlangen, Germany. Isabel received a BS in Biomedical Engineering with a minor in International Affairs from the Georgia Institute of Technology where she participated in the honors program and international plan. In addition, Isabel studied abroad at UC3M in Madrid, Spain.

 

Maryan Zirkle, MD, MS, MA
Executive Director, BRAINCommons

View Bio

Maryan Zirkle, MD, MS, MA

Executive Director, BRAINCommons

Maryan Zirkle MD, MS, MA is an accomplished professional with more than 10 years of experience working in the research industry. She has expertise in research network infrastructure development and sustainability, Big Data, patient-centered outcomes research, healthcare delivery and medicine, mental health, interdisciplinary-based team management, contract management, and active research portfolio management.

Before joining Cohen Veterans Bioscience, Dr. Zirkle was the Associate Director of the Research Infrastructure team at the Patient-Centered Outcomes Research Institute (PCORI). She was responsible for providing intellectual and organizational oversight for the development and regulation of PCORI’s National Patient-Centered Clinical Data Research Network, PCORnet. Zirkle has also worked as a research health science specialist at the Department of Veterans Affairs. She gained considerable experience in polytrauma, traumatic brain injury (TBI), posttraumatic stress disorder (PTSD) and medical informatics research at Department of Veterans Affairs (VA) medical centers in Tampa, Florida, and Portland, Oregon. She completed a three-year advanced fellowship in clinical informatics at the VA in Portland. She also received two bachelor of arts degrees from the University of Florida, a master of arts in rehabilitative and mental health counseling from the University of South Florida, a master of science in biomedical and clinical informatics from Oregon Health and Science University, and a medical degree from Spartan Health Sciences University.

Seung Lee
Associate Director, Product Management, BRAINCommons

View Bio

Seung Lee Associate

Director, Product Management, BRAINCommons

Seung is an experienced Agile practitioner and certified Professional Scrum Master with over a decade of experience managing software development, system integration, and testing in a web application environment; User Interface, Database, Web services and API’s. He possesses technical QA and a very detail-oriented background with the ability to understand and communicate with all levels of the organization, both in technical & functional settings. He has in-depth knowledge with Software Development Life Cycle (SDLC) involving Agile methodologies and other software development methods. In his off-time, he enjoys hanging out with his wife and 3 kids and playing basketball. He is also a life-long Knicks fan.

Donnárd Sturgis
QA Technical Writer, BRAINCommons

View Bio

Donnárd Sturgis

QA Technical Writer, BRAINCommons

Donnárd Sturgis has more than 20 years of experience as a Technical Writer, across a number of market sectors, including Healthcare Diagnostics, Finance, and Telecommunications. He also worked for a number of years as a Software Developer. Donnárd earned his BS in Computer Science from the Illinois Institute of Technology.

External Affairs

Chantelle Ferland-Beckham, PhD
Senior Director, External Affairs

View Bio

Chantelle Ferland-Beckham, PhD

Senior Director, External Affairs

Dr. Chantelle Ferland-Beckham is a translational neuroscientist by training, with over 15 years of experience in preclinical models of neuropsychiatric disorders and brain injury models. She is also an experienced public policy and advocacy professional, having spent nearly 10 years working on advocacy and public policy issues at the local, state and federal levels. After earning her PhD in Neuroscience from Tulane University, she went on to complete postdoctoral fellowships in both traumatic brain injury and clinical and preclinical models of comorbid addition and post-traumatic stress disorder (PTSD). She was later selected to be an AAAS Science & Technology Policy Fellow at the National Institutes of Health. In this role as a Health Science Policy Analyst, she evaluated research programs and developed policies to promote progress in biomedical research and ensure the effective use of taxpayer funds to conduct research for the benefit of human health. She also assisted with Congressionally mandated reporting and liaison activities to strengthen the relationship between the NIH and Congress. Additionally, she worked on the Fellows in Innovation initiative, spearheaded by the Obama administration’s Office of Science and Technology Policy, to analyze current strategies and provide policy recommendations for suicide prevention in current and former members of the US military. In 2017, she joined Cohen Veterans Bioscience (CVB), serving in a capacity that bridged her scientific and public policy backgrounds and supporting both the programmatic and policy initiatives of CVB.

Operations

Lauren J. Goldsmith
Senior Director, Contracts and Grants Management

View Bio

Lauren J. Goldsmith

Senior Director, Contracts and Grants Management

Lauren is a contracting professional with over 18 years in the pharmaceutical industry with specialized expertise in outsourcing and contracting for all R&D activities for clinical and preclinical trials. She also has experience in supporting corporate agreements, research collaborations with academic institutions, and vendor relationship management.

Before joining Cohen Veterans Bioscience, she was the Global Head of Site Contracts leading an international department of over 25 people globally.

Lauren graduated from Harvard University with a Bachelor of Liberal Arts and holds a Paralegal Certificate from Northeastern University. She has also holds a Certificate in the Fundamentals of the Bioscience Industry from The Center for Biotechnology from Stony Brook University.

CEO/Finance Office

Elinor Litwack, CPA
Finance Comptroller (Contract)

View Bio

Elinor Litwack, CPA

Finance Comptroller (Contract)

Elinor Litwack is Partner at GRF CPAs and Advisors’ outsourced accounting and advisory team. Over the past decade she has specialized in providing financial and organizational solutions to nonprofit organizations, utilizing state of the art technology combined with deep industry expertise. She is proficient in systems design, cloud computing, audit readiness and accounting best practices. As contract finance manager, Elinor leads the finance team at CVB.

Elinor serves as Treasurer of I Support the Girls, a nonprofit organization that facilitates donations of bras and menstrual hygiene products to women and girls experiencing homelessness. A graduate of George Washington University, Elinor was nominated for the Greater Washington Society of CPAs’ Women to Watch Awards in 2015. Additionally, Elinor was recognized in NYN Media’s 2021 Nonprofit 40 under 40.

Elinor is a member of the American Institute of Public Accountants, the Maryland Association of Certified Public Accountants and the New York State Society of CPAs, where she serves on the Chief Financial Officer committee. Additionally, Elinor participated on the planning committee for the 2021 Better Business Bureau of New York’s Charity Effectiveness Symposium and is serving as the 2021 Digital CPA Advisory Board Chair. Elinor lives in Englewood, New Jersey with her husband and four kids.

Communications

Michael Carson
Head of Communications

View Bio

Michael Carson

Head of Communications

Michael Carson is the Head of Communications of Cohen Veterans Bioscience, the New York-based non-profit organization dedicated to advancing brain health.

Prior to Cohen Veterans Bioscience (CVB), Michael served as chief marketing officer of the Alzheimer’s Association leading strategic initiatives that drove the global conversation of early detection, diagnosis of Alzheimer’s disease and other dementia, and awareness initiatives in support of brain health. Michael’s role supported organizational advancements in advocacy and research.

Michael led the Association’s organizational branding, global communications and digital revenue streams. In addition to publishing initiatives Michael oversaw alz.org, social platforms, global media relations, celebrity engagement, advertising and internal communications for all staff.

Under Michael’s leadership, the Association has grown concern about Alzheimer’s disease and awareness of the organization and its programs and services. Reach among the public has significantly increased and Michael made significant social media gains in reach, engagement and revenue growth. Michael’s forward-thinking approach to new programs and initiatives has heightened concern, reduced stigma and advanced the cause.

Prior to joining the Alzheimer’s Association, Michael led marketing and operations as executive vice president and chief marketing officer for an ad- supported tech-based start-up venture. He also held marketing leadership roles at FTD.com, Ogilvy & Mather, Orbitz Travel and FCB.

He served on the Google App Developer Council, the Discover Financial Services Merchant Advisory Board and the Meta Social Good roundtable.

Michael received a master’s degree in business administration from the University of Notre Dame and a bachelor’s degree in business administration and marketing from Marquette University.

Learn More About CVB

Recent News

Events

Featured Articles

Get the latest updates from CVB by signing up for our Newsletter

Name
I would like updates on:

By submitting this form, you are consenting to email communications from CVB.

Current Openings

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

These brave men and women voluntarily stepped up on the line to serve this great nation with the goal of protecting our freedoms…many have gone into harm’s way at personal expense and sacrifice. We cannot leave any more of them behind. It is our national obligation to support those that have come home with both visible and invisible wounds.

Frank Larkin
Chair

View Bio

Frank Larkin
Chair (Consulting),
Veterans Advisory Council

Frank Larkin was formerly the United States Senate Sergeant at Arms (SAA). As chief law enforcement and executive officer of the Senate, the SAA enforces rules of the Senate; provides a range of technical and administrative services to Senators in their Washington, DC, and state offices; and maintains security in the Capitol and Senate office buildings.

Frank was a member of the Senior Executive Service, recently serving as both the Acting Director and the Vice Director of the Joint Improvised Explosive Device Defeat Organization (JIEDDO) within the Department of Defense. He previously served as JIEDDO’s Director for the Counter IED Operations-Intelligence Integration Center. JIEDDO’s mission was to focus all Department of Defense actions in support of the combatant commanders’ efforts to defeat improvised explosive devices (IEDs) as weapons of strategic influence. Frank’s focus was in support of our deployed warfighters and special operations forces around the globe and the integration of a “whole of government” disruption effort targeting extremist networks that employ IEDs.

Frank served for more than two decades in the United States Secret Service (USSS), beginning in 1984 as a Special Agent assigned to the Philadelphia and Washington Field Offices, before assignment to the Presidential Protective Division. He was assigned to the Office of Congressional Affairs for a two-year fellowship on Capitol Hill, serving a year each with the Senate and House Appropriations Committees. Frank entered the USSS supervisory ranks as Assistant to the Special Agent in Charge of the New York Field Office, where he led financial, electronic, and organized crimes investigations. Following the events of 9/11, he returned to Washington, DC, as the Assistant Special Agent in Charge of the Presidential Protective Division, supervising White House security operations. As Assistant Special Agent in Charge of the Technical Security Division, Frank was responsible for tactical countermeasures programs. In 2004, he was promoted to the Senior Executive Service, assuming the position of Deputy Assistant Director for Protective Research and Chief Technology Officer.

Following his USSS career, Frank was Director, Program Management & Leadership, for the Raytheon Company, and more recently, worked at Lockheed Martin’s Defense & Intelligence Solutions, responsible for providing operations and intelligence analysis support to the intelligence community.

A veteran of the US Navy, Frank has a significant military and law enforcement special operations background, serving as a special warfare operator in the Navy SEALs. After his Navy service, he was a uniformed patrol officer with the Norristown (PA) Police Department, a homicide detective with the Montgomery County (PA) District Attorney’s Office, and a Maryland State Trooper-Flight Paramedic.

Frank holds a BA degree in criminal justice and an MS degree in public administration from Villanova University. He is the recipient of numerous awards, including the US Secret Service award for valor, the Department of the Army’s Exceptional Civilian Service award, and the Superior Civilian Service award.

I think the two most urgent needs are to establish the most effective treatment protocols that are tailored to the individual’s situation…and to determine the most effective ways to prevent traumatic brain injury and post-traumatic stress and preserve long-term resiliency and brain health.

Brian Losey, RADM, U.S. Navy (Ret.)
Executive Director

View Bio

Brian Losey, RADM, U.S. Navy (Ret.)
Executive Director (Consulting),
Veterans Advisory Council

Brian transitioned from 33 years of service in the U.S. Navy and Special Operations community in 2016.  He commanded U.S. Naval Special Warfare Command, U.S. Special Operations Command Africa, Combined Joint Task Force-Horn of Africa, Naval Special Warfare Development Group, and SEAL Delivery Vehicle Team ONE.  He served in key command and staff positions in Task Forces deployed to Afghanistan, Iraq, and Africa, and has significant experience in named and contingency operations around the world.  He served as a Director for Combatting Terrorism and Director for Maritime Security on the National Security Council Staff under the Bush and Obama Administrations.  Brian guides product and business development for Shield AI, a leading company in the fielding of autonomous and artificially intelligent robotic systems for the security sector.   In Commons Federated, LLC, Brian also serves as a consultant, advisor and board member to cutting edge technology enterprises seeking market growth in U.S. Government markets.

The VAC’s Goals

  1. Share Veterans’ perspectives, challenges, and needs to inform research that will help improve the health of Veterans
  2. Lead awareness efforts to build support for researching brain trauma solutions from within and outside of the Veterans’ community
  3. Increase collaboration across the community to help prevent, diagnose, and treat PTSD, TBI, and other co-morbid conditions
  4. Reinforce legislation to advance the execution of a comprehensive plan that accelerates PTSD and TBI research.
  5. Raise awareness of brain trauma as a risk factor for suicide and drive efforts to address suicide through research.
Play Video

The VAC’s Advocacy Priorities

  1. Improving Veterans’ access to high-quality mental health care
  2. Leveraging large-scale collaborative research roadmapping efforts
  3. Increasing the body of evidence on emerging therapeutic solutions
  4. Ensuring full implementation of important mental health legislation

Council

Bob Harward, VADM (SEAL), U.S. Navy (Ret.)
Member, Veterans Advisory Council

View Bio

Bob Harward, VADM (SEAL), U.S. Navy (Ret.)
Member, Veterans Advisory Council

Bob Harward is the Chief Executive (CE) for Lockheed Martin Middle East and has lived in Abu Dhabi for five years. In his role as CE, he is responsible for all aspects of the company’s business in UAE, Bahrain, Kuwait, Oman, Jordan, Lebanon, Qatar, Pakistan, Iraq and Afghanistan, including strategy, operations, and profitable growth of Lockheed Martin business. He was recognized by Forbes (Oct 2019) as one of the fifty (# 10) most influential CEO’s in the Middle East.

A National Security Expert, in both theory and application, he served on the National Security Council for the Bush administration, commissioned the National Counter Terrorism Center, and has extensive combat experience as a US Navy SEAL, in Afghanistan, Iraq (he led invasions in both countries in Oct 2001 and Mar 2003), Syria, Somalia, Yemen and Bosnia, as well as the rest of the Middle East. He was recently asked by President Trump to serve as his National Security Advisor. A US Naval Academy alumni, he holds a Masters degree in International Security Affairs, is a graduate of the Naval War College and the MIT Foreign Policy Program. He also served as an executive fellow at RAND. Prior to joining Lockheed Martin, he was a Vice Admiral (SEAL) in the United States Navy, with his last assignment as Deputy Commander, US Central Command (USCENTCOM). Mr. Harward grew up in Iran, graduated from the Tehran American School and speaks Farsi.

Mr. Harward’s significant recognitions include the Donovan Award from the CIA, the Distinguished Service Award from the Department of State, the German Silver Star, the Polish Silver Star, and he was designated a Commander of the Polish GROM (Special Operation Forces). The Department of Defense awarded him the Defense Distinguished Service Medal (three), the Navy Distinguished Service Medal, the Bronze Star with V device (four), and the Presidential Unit Citation (two) for combat operations in Afghanistan and Iraq. He was also recognized with the US Naval War College Distinguished Graduate Leadership Award.

Aside from his responsibilities with Lockheed Martin, Bob serves on the Secretary of Defense Threat Reduction Advisory Committee (TRAC) where he chair’s the Counter Weapons of Mass Destruction Task Force, is an advisor to Draper Labs, adjunct to RAND, an ABC contributor and sits on several commercial boards to include Channel, USAA REALCO and Shield AI. On the personal side, Bob is a Professional Parachutist, performing around the world and enjoys all forms of physical and intellectual competition, particularly chess, racquetball, golf and squash. He set the World Record for the highest parachute landing on the West Col Base Camp of Mount Everest at over 21,000 feet on 27 October 2019.

Robin King
Member, Veterans Advisory Council

View Bio

Robin King
Member, Veterans Advisory Council

Robin King is the Chief Executive Officer for the Navy SEAL Foundation, a 501(c)(3) national nonprofit organization that provides critical support and assistance to the Naval Special Warfare (NSW) community and its families.

Ms. King has been with the Navy SEAL Foundation since its inception in July 2000, and in that time has served as Chief Financial Officer, Deputy Executive Director, and Interim Executive Director before being appointed as Chief Executive Officer in May of 2013. Her exemplary leadership and commitment to financial transparency and accountability have allowed the Foundation to grow from a small organization focused on scholarships and educational opportunities to a multi-faceted programmatic foundation with dozens of specialized programs and an annual program budget in the millions.

Ms. King executes the daily mission of the Navy SEAL Foundation from Coronado, California, home of Naval Special Warfare Command (WARCOM), SEAL Qualification Training and the headquarters of NSW. She leads a staff of nearly twenty employees located throughout the United States. Under her command, the Navy SEAL Foundation has consistently achieved and maintained the highest rating possible from Charity Navigator, a national charity watchdog organization, placing it in the top 1% of all charities rated.

In August of 2019, Ms. King was awarded the prestigious United States Special Operations Command (USSOCOM) Outstanding Civilian Service Medal which recognized her steadfast dedication and superior service to the NSW community including raising millions of dollars to fund programs touching the lives
of tens of thousands of NSW warriors and families.

In 2017, Ms. King was awarded the USSOCOM Care Coalition Patriot Award. This distinguished award recognizes individuals and organizations who greatly support Special Operations Force (SOF) wounded warriors, their families, and surviving family members by providing significant and enduring
contributions that benefit their care and recovery. She is the first nonprofit leader to receive this award.

Ms. King is a current member of the Board of Directors for The Honor Foundation and the C4 Foundation, both nonprofits serving the Naval Special Warfare community.

Before her employment at the Foundation, Robin worked at Pacific Trust Bank, The Walt Disney Company, and McDonnell Douglas Corporation (Boeing). She holds a Bachelor of Science degree in Business Administration, Finance, from California State University, Long Beach.

LTG John F. Mulholland, U.S. Army (Ret).
Member, Veterans Advisory Council

View Bio

LTG John F. Mulholland, U.S. Army (Ret).
Member, Veterans Advisory Council

The proud son of a USAF fighter pilot and Korean War veteran, Lieutenant General Mulholland John Francis Mulholland, Jr. (Retired) was born in Clovis, New Mexico, but grew up in Bethesda, Maryland. He earned a Bachelor of Arts in History and was commissioned as a Second Lieutenant of Infantry, United States Army upon graduating from Furman University, Greenville, South Carolina, in 1978.

As a young Infantry officer, LTG Mulholland (Ret) served as platoon leader of both mechanized and airborne rifle platoons, as well as mortar platoon leader. Since joining the 1st Special Forces Regiment in 1983, LTG Mulholland (Ret) commanded from the captain through lieutenant general-level in Army and joint special operations forces, including serving as Deputy Commanding General, Joint Special Operations Command, as the Commanding General, United States Army Special Operations Command, and as the 15th Deputy Commander, United States Special Operations Command. Following graduating from the National War College in 2001, then-COL Mulholland assumed command of the 5th Special Forces Group, Airborne at Ft. Campbell, KY. In the immediate aftermath of the attacks of 9-11, Colonel Mulholland commanded Joint Special Operations Task Force-North (Task Force Dagger) in the opening days of Operation ENDURING FREEDOM and, later, Combined Joint Special Operations Task Force-West (Task Force Dagger) in the initial campaign of Operation IRAQI FREEDOM.

LTG Mulholland’s (Ret) overseas assignments included two tours in the former Panama Canal Zone, command of the 1st Battalion, 1st Special Forces Group (ABN), Okinawa, Japan and as the Chief, Office of Military Cooperation, Kuwait. LTG Mulholland (Ret) served at and completed his final tour on active duty as the Associate Director of Military Affairs, Central Intelligence Agency. LTG Mulholland (Ret) is married to the former Miriam Mitchell. Together, they have 4 grown children and 5 grandchildren. LTG Mulholland (Ret) and Miriam now operate Mulholland Consulting, LLC in Alexandria, Virginia.

Tim Szymanski, VADM, U.S. Navy (Ret.)
Member, Veterans Advisory Council

View Bio

Tim Szymanski, VADM, U.S. Navy (Ret.)
Member, Veterans Advisory Council

Tim has served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years. He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW). In both roles he oversaw the manning, equipping and training, and employment of NSW and joint special operations forces, of 11,000 and 73,000 uniformed and civilian personnel, respectively.

He has an extensive background in raising, equipping, and training Navy, allied and joint special operations forces and has served operationally in Iraq, Afghanistan, Haiti, and other places of crises. As Deputy Commander USSOCOM and as Commander NSW he spearheaded force design and development initiatives, led organizational culture reviews and implementation plans, and developed leaders throughout the force.

Keenly aware of the detrimental effects of invisible wounds on Force and Family Readiness, he established policies and developed lines of effort to monitor, protect and enhance warfighter brain health.

More from our VAC

Magali Haas, MD, PhD
Board Chair

View Bio

Magali Haas, MD, PhD

Board Chair

Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early and late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.

Michael Sullivan
Board Treasurer

View Bio

Michael Sullivan

Board Treasurer

Michael C. Sullivan is the Chief of Staff and Head of External Affairs of Point72 Asset Management. Mr. Sullivan joined the Firm in 2007 after serving as a senior aide in the United States Senate, focusing on telecom, technology, and finance issues. Mr. Sullivan also served as a staff member in the U.S. House of Representatives working on similar issues. Before coming to Capitol Hill, Mr. Sullivan was the head of strategic development for a telecommunications focused trade association.

Mr. Sullivan is involved with several veterans’ mental health-related non-profit organizations. He helped establish and serves on the Board and as Treasurer of the Cohen Veterans Network, which operates a national network of clinics to treat veterans and their family members affected by Post-Traumatic Stress. Mr. Sullivan also serves as the Treasurer and on the Board of a second veterans-oriented non-profit, Cohen Veterans Bioscience, which is developing next-generation diagnostics and therapeutics to improve the detection and treatment of Post-Traumatic Stress.

Mr. Sullivan is an Associate at the NYU-Stern Endless Frontier Labs, where he mentors start-up companies in artificial intelligence, machine learning, and related fields. He is also a member of the Executive Committee of Students First New York, a nonprofit organization advocating for educational reform in New York State. Mr. Sullivan is a graduate of Vanderbilt University.

Theresa Frangiosa
Board Secretary

View Bio

Theresa Frangiosa

Board Secretary

Board Member, Secretary, Theresa Frangiosa held executive positions in the pharmaceutical industry over a 25 year career before establishing Frangiosa and Associates, LLC in 2013, where she serves as Principal and Chief Executive Officer and provides guidance on a broad range of strategic decisions, integrating expertise into product and disease strategies, medical and scientific communications and patient and caregiver advocacy efforts. Her interest in Advocacy has resulted in long-standing support of several organizations dedicated to patient support in Brain Disorders and Breast Cancer and she participates on several Boards.

Her husband is a retired Navy Captain (Judge Advocate General’s Corps), and she was a long-time Dementia patient caregiver for her mother who had Alzheimer’s Disease. In addition to her service with UsAgainstAlzheimer’s, Ms. Frangiosa serves on the Board of Schizophrenia and Related Disorders Alliance of America (SARDAA).

Ms. Frangiosa has proven success demonstrated in a career as a Pharmaceutical Executive that spanned 25 years. In her roles within Pharma, she was a Global Launch Leader as well as overseeing Early Commercial Strategy in Neurosciences. She led large scale teams, cross-functional teams to define disease and therapeutic area strategies for Janssen and GlaxoSmithKline. She has also led indication prioritization efforts and development of over 200 Target Product Profiles over a variety of disease states, leveraging well-established processes and frameworks, including deeper understanding of patient journeys to create key insights.

She has applied her professional career experience and her passion for advocacy to help create a channel for feedback from those diagnosed with or at risk for Alzheimer’s Disease or Dementia, their care partners and individuals who are ‘worried well’, called the A-LIST. She is the lead investigator for this research study with IRB oversight.

Ms. Frangiosa obtained her Bachelor of Administration, Accounting Concentration from Ursinus College (Collegeville, PA) in 1988 and her Masters of Business Administration, Pharmaceutical Marketing from St. Joseph’s University in 1996.

David M. Biondi, DO, FAAN
Board Member

View Bio

David M. Biondi, DO, FAAN

Board Member

David Biondi received his medical degree from the University of New England, College of Osteopathic Medicine in Biddeford ME. He completed residency training in Neurology at the National Naval Medical Center in Bethesda MD and is board-certified in Neurology with subspecialty expertise in Headache and Pain Medicine. He received his Bachelor of Science – Magna Cum Laude in Pharmacy from the Long Island University, Schwartz College of Pharmacy & Health Science in Brooklyn NY.

Dr. Biondi has over 15 years of experience in clinical research and development of pharmaceuticals and medical devices in the neurology, psychiatry, and pain therapeutic areas. His experiences include the design, implementation, monitoring, and interpretation of phase 2 to phase 4 clinical trials and in-house and field-based activities associated with insights generation, new business opportunities, emerging health policy, knowledge translation and implementation, and organizational effectiveness. He previously served as Executive Director for Clinical Programs with Cohen Veterans Bioscience.

Dr. Biondi has over 20 years of clinical experience in medical practice and held medical directorships at the US Naval Hospital in Okinawa Japan, the Pain Management Program & Headache Institute at Maryview Medical Center in Portsmouth VA, the Pain Division of the Michigan Head Pain & Neurological Institute in Ann Arbor MI, and the Interdisciplinary Headache & Pain Rehabilitation Program at Spaulding Rehabilitation Hospital in Boston MA. He was previously an Assistant Neurologist at the Massachusetts General Hospital and an Instructor in Neurology at Harvard Medical School.

Dr. Biondi served as a trustee for the University of New England and was Chair of its Academic and Research Affairs committee and Vice-Chair of its Long-Range Planning committee. He also served as a Director and medical advisor for the After Action Network, a nonprofit Veteran Service Organization in Kansas City MO. He is a Fellow of the American Academy of Neurology.

Dave DeMarco, PhD
Board Member

View Bio

Dave DeMarco, PhD

Board Member

Dr. Dave DeMarco is a senior advisor to C-suite leaders in the Life Sciences and Healthcare industries. He serves as Chief Strategy Officer for Material Health Strategies and works with c-suite executives on growth strategies and team performance in both the for-profit and non-for-profit industries. He previously served as Chair of the Board of the American Diabetes Association, led Ernst & Young’s (EY’s) Northeast Life Sciences practice and was the Deputy Leader of the US Healthcare Practice.

With over 25 years of leadership experience, Dave advises, coaches and shares insights on strategy and transformation, commercial operations, hHealthcare policy, governance, public-private-partnerships, and entrepreneurial growth.

While serving on the board of the American Diabetes Association, he led Board initiatives involving: CEO succession, Principal Officer succession, Board Development, Policy creation, strategic plan implementation and technology partnerships.

Dave has held key executive positions, including: Global Aesthetic Franchise Leader, Sanofi Aventis; US Health Deputy Leader, Northeast Region Life Sciences Practice Leader and Johnson & Johnson Global Client Services Partner, EY; Research Scientist, Internal Venture Leader, Amoco Chemical; and cofounder, Idea Connection Systems.

Dave worked closely with the Aventis NA leadership team to develop post-merger integration growth strategies and launch key blockbuster products aimed at, and succeeding in, doubling the size of the business in four years. As a senior partner in EY’s Global Life Sciences team, Dave piloted a new P&L accountable, go-to-market model, growing the Northeast practice at 30% CAGR, resulting in a $400 million business. In his service to Johnson & Johnson, he partnered with J&J leadership in developing Janssen Healthcare Innovation, charged with creating future business units. Dave led the transformation of EY’s US Health practice, resulting in a $750 million business. As a member of the Sanofi Aventis NA Dermatology leadership team, Dave developed the global aesthetic franchise strategy and served as the commercial head for Europe. For this turnaround project, he created a plan to triple EBITDA, implement new global pricing policies and double customer acquisition.

Dave received his B.S. from Grove City College and Ph.D. in chemistry from Purdue University.

Learn More About CVB

We’re leading a new approach in research, diagnosis, treatments and advocacy for PTSD and TBI.

By combining the power of biotechnology with rigorous research, high-performance computing, and data analytics, we’re accelerating the development of precision diagnostics and tailored treatments for military service members, Veterans, first responders, and all people living with the effects of brain trauma.

We advocate for people with brain trauma through a focused advocacy strategy that includes our Veterans Advisory Council, ongoing outreach to Congress, and dedicated educational programs.

Our goal is to advance tailored treatments for PTSD and TBI so that a clinician can target the right treatment to the right person at the time when they need help most.

Leveraging the right approach, the right tools, and the right partners.

CVB will achieve our mission to deliver solutions to people suffering from brain trauma by leading in multiple areas:

Research & Development

Researching and developing objective diagnostic tools that detect the underlying biology of brain trauma and treatments, including preventative wellness, digital health, drug and device approaches.

Collaboration

Convening the brightest minds in the PTSD and TBI research communities because collaboration, data sharing, and leveraging each partner’s unique capabilities is the fastest way to deliver impactful solutions to patients.

Tools & Platforms

Developing research tools & platforms which leverage our own technology and innovative approaches to enable our partners to conduct research that can scale & accelerate the development of effective solutions for brain trauma. 

Advocacy

Shaping the environment for cutting-edge research by providing education to researchers on best practices and by fostering support for advancing brain trauma solutions at the federal, state and local levels through advocacy and education. 

In the future we will be able to apply our discoveries to advance solutions to optimize brain health for all populations.

Learn more about our research here. Or make a difference and support our work by making a donation today.

Donate Now

Learn More About CVB

It seems we can't find what you're looking for.

Name(Required)
How can we help you?
Consent

Cohen Veterans Bioscience welcomes any questions or comments you may have.

New York Office (Main Office)
535 8th Ave, 12th floor
New York, NY 10018
Phone: (646) 970-4325

Cambridge Office
1 Broadway, 14th Floor
Cambridge, MA 02142

Cohen Veterans Bioscience (CVB) is a non-profit 501(c)(3) public charity research organization and does not offer medical advice. CVB encourages you to seek medical advice from a physician or healthcare provider if you have questions regarding a medical condition, or to call 911 or go to the nearest hospital if you find that you or someone you are concerned about is in an emergency situation.

Cohen Veterans Bioscience accepts requests for funding proposals by invitation only. CVB strategically leads and funds projects that align with our mission and current initiatives.